Table 2.
Univariate analysis for survival in 454 patients with distal pancreatic adenocarcinoma
| Variable | Progression-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex (male vs female) | 1.01 (0.77–1.32) | 0.94 | 1.10 (0.88–1.37) | 0.39 |
| Age (every 1-year increase) | 0.99 (0.98–1.00) | 0.07 | 1.01 (1.00–1.02) | 0.13 |
| Tumor size (every 1-cm increase) | 1.11 (1.04–1.18) | 0.001 | 1.10 (1.04–1.15) | <0.001 |
| Diagnosis group (non-IPMN vs IPMN) | 2.62 (1.71–4.02) | <0.001 | 1.94 (1.41–2.66) | <0.001 |
| Differentiation | ||||
| Well | Reference | – | Reference | |
| Moderate | 1.46 (0.89–2.39) | 0.14 | 1.26 (0.83–1.90) | 0.28 |
| Poor | 1.75 (1.03–2.96) | 0.04 | 1.88 (1.22–2.90) | 0.004 |
| T category | ||||
| T1 | Reference | – | Reference | – |
| T2 | 1.97 (1.27–3.05) | 0.002 | 1.26 (0.90–1.75) | 0.18 |
| T3 | 2.27 (1.45–3.56) | <0.001 | 1.75 (1.25–2.46) | 0.001 |
| N category | ||||
| N0 | Reference | – | Reference | – |
| N1 | 1.93 (1.45–2.58) | <0.001 | 1.78 (1.40–2.27) | <0.001 |
| N2 | 1.98 (1.30–3.02) | 0.001 | 2.04 (1.46–2.84) | <0.001 |
| Lymphovascular invasion (small vessel) | 1.65 (1.25–2.17) | <0.001 | 1.49 (1.19–1.87) | <0.001 |
| Perineural invasion | 1.55 (1.08–2.23) | 0.02 | 1.60 (1.18–2.18) | 0.003 |
| Pathologic SA invasion | 1.81 (0.99–3.29) | 0.05 | 1.44 (0.89–2.31) | 0.13 |
| Pathologic SV invasion | 1.93 (1.23–3.04) | 0.004 | 2.21 (1.57–3.11) | <0.001 |
| Splenic parenchymal invasion | 2.02 (1.19–3.41) | 0.009 | 1.40 (0.89–2.20) | 0.15 |
| Adjuvant radiation therapy | 0.98 (0.74–1.28) | 0.86 | 0.86 (0.67–1.10) | 0.23 |
| Adjuvant chemotherapy | 1.68 (1.09–2.59) | 0.02 | 0.57 (0.43–0.75) | <0.001 |
| Radiographic SA invasion | 1.47 (1.04–2.07) | 0.03 | 1.25 (0.91–1.71) | 0.17 |
| Radiographic SV invasion | 1.45 (1.05–2.01) | 0.02 | 1.55 (1.16–2.08) | 0.003 |
IPMN, intraductal papillary mucinous neoplasms; SA, splenic artery; SV, splenic vein; HR, hazard ratio; CI, confidence interval.